ERBB2 and gastric cancer: Other HER-2-targeted agents, such as margetuximab [73], tucatinib [74], neratinib (NCT06109467), zanidatamab [53], and ARX788 [75], are being tested in the palliative setting of HER-2-positive gastric cancer and have not yet been included in trials in the perioperative setting.